GeoVax Labs Engages The Investor Relations Group

SMYRNA, Ga., March 22 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), a thirteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency.

"GeoVax Labs has outlined several important initiatives for 2010, and we are confident that IRG will have a great story to tell," commented Robert T. McNally, President and Chief Executive Officer.  "We are proud of GeoVax's progress to date in developing preventative vaccines designed to protect HIV-free individuals from developing AIDS, as well as therapeutic vaccines designed to protect individuals with HIV from progressing to AIDS.  Our vaccines have exhibited encouraging results in clinical trials, and these trials are ongoing.  With HIV infection rates among certain groups on the rise around the globe, we feel our efforts are timely and of critical importance for public health.  We look forward to working with IRG as we achieve our objectives and will update the investment community as we move ahead."

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents.  Our goals include developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting human trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.  All preventative phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA AIDS vaccines in human volunteers for their demonstrated ability to raise anti-HIV immune responses as well as for their safety.  Successful results from all phase 1 testing supported the initiation of the first phase 2 testing.  GeoVax's phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America.  Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues.  Internal vaccine manufacturing and distribution will also be considered by GeoVax.  For more information, please visit www.geovax.com.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies.  The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large.  For further information, please visit the company's website at http://www.investorrelationsgroup.com.

IRG's corporate communications program includes new media and multimedia initiatives that involve the creation of broadcast-ready corporate videos, podcasts, and the creation of social networking, video service, and micro-blogging accounts.  The Investor Relations Group was recently honored with a "Stevie Award" for Investor Relations Program of the Year and named a finalist in the Best Media Website category from the 2009 American Business Awards.

Forward-looking Statements:  Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors, including whether:  GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.